Glenmark Pharmaceuticals Ltd has announced its plans to launch Eribulin Mesylate Injection, a critically important chemotherapy drug used in breast cancer treatment, in the United States market. The company will commence distribution of this product in September 2025, marking a strategic expansion of Glenmark’s oncology portfolio in one of the world’s largest pharmaceutical markets.
Product and Therapeutic Use
Eribulin Mesylate Injection (0.5 mg/mL single-dose vial) is a generic equivalent to Eisai Inc.’s Halaven and is prescribed for the treatment of locally advanced or metastatic breast cancer, and liposarcoma, among other conditions. It functions by inhibiting cancer cell growth and proliferation.
Regulatory Approval and Market Potential
The drug has received United States Food and Drug Administration (USFDA) approval, validating its bioequivalence and therapeutic equivalence to the branded counterpart. According to IQVIA data, the reference product Halaven achieved annual sales of approximately USD 92 million in the US market for the twelve months ending February 2024, indicating strong market potential.
Glenmark’s Strategic Oncology Expansion
This launch is part of Glenmark’s broader strategy to strengthen its oncological offerings and institutional sales in the US. The company’s North American business head, Marc Kikuchi, emphasized the commitment to delivering affordable and high-quality treatments to patients, expanding access to critical cancer medications.
Distribution and Marketing Plans
Glenmark Pharmaceuticals, USA, a wholly-owned subsidiary, will manage distribution through established pharmaceutical channels with a focus on institutional buyers such as hospitals and oncology clinics. The introduction of single-dose vials is designed to align with medical needs and improve patient compliance.
Collaborations and Development Pipeline
The company continues to co-develop complex injectable products with partners like Orbicular Pharmaceutical Technologies Pvt Ltd, reinforcing Glenmark’s standing in the generic oncology injectable segment. This synergy is expected to yield several additional pipeline products in the coming years.
Impact on Glenmark’s Market Position and Revenue
The entry of Eribulin Mesylate Injection into the US market is anticipated to add significant revenue streams and enhance Glenmark’s competitive positioning. Expansion in high-value therapeutic areas like oncology complements existing product lines and diversifies risk across geographies and therapies.
Global Oncology Market Context
With cancer rates rising globally and growing demand for cost-effective treatments, generic oncology drugs such as Eribulin provide affordable alternatives to branded medications, improving accessibility. The US remains a key battleground for generic pharmaceutical companies, and Glenmark’s USFDA approvals highlight its capability to compete effectively.
Conclusion: Strategic Milestone for Glenmark in the US Oncology Market
Glenmark Pharmaceuticals’ decision to launch Eribulin Mesylate Injection in the US, with distribution starting September 2025, represents a strategic milestone reinforcing its commitment to impactful therapies in oncology. This move is expected to strengthen Glenmark’s presence and drive growth in advanced pharmaceutical markets, supporting its vision of providing accessible, affordable healthcare solutions worldwide.
Sources: Economic Times, Financial Express, Glenmark Pharmaceuticals official statements, IQVIA market data, Business Standard
